Board Member
Lexicon Pharmaceuticals, Inc. (LXRX)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Michael Exton, Ph.D. is recorded as CEO and Board Member at Lexicon Pharmaceuticals, Inc. (LXRX). Lexicon Pharmaceuticals, Inc. reported in an 8-K filed July 8, 2024 that Michael Exton, Ph.D. was appointed member of our board of directors, effective July 8, 2024. Lexicon Pharmaceuticals, Inc. reported in an 8-K filed July 8, 2024 that Michael Exton, Ph.D. was appointed chief executive officer, effective July 8, 2024. Michael Exton, Ph.D. has spoken on 3 earnings calls across 1 company, most recently for Lexicon Pharmaceuticals, Inc. on May 7, 2026.
“Effective as of July 8, 2024, Michael Exton, Ph.D. was appointed as our chief executive officer (in which capacity he will function as our principal executive officer) and elected to serve as a member of our board of directors.”
“Effective as of July 8, 2024, Michael Exton, Ph.D. was appointed as our chief executive officer (in which capacity he will function as our principal executive officer) and elected to serve as a member of our board of directors.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2024-07-08–present
2024-07-08–present
Recorded roles and call appearances connecting this person to public companies.
CEO, Board Member
2024-07-08–present
Other people whose current roles at this company are on record from its filings.
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
